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Somatostatin, an hyperglycemia-inducing hormone, was studied in rat insulinoma (RINm5F) cells using 8~Rb + efflux 
techniques. ~Rb + efflux is stimulated by somatostatin i  a dose-dependent manner. The half-maximum value of activa- 
tion is 0.7 nM. Somatostatin-induced S6Rb+ efflux is abolished by the hypoglycemia-inducing sulfonylurea, glibenclamide, 
a known blocker of ATP-regulated K + channels. Somatostatin activation is prevented by pretreatment of insulinoma 
cells with pertussis toxin. S6Rb + effiux studies how that somatostatin activates an ATP-dependent K ÷ channel. 
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1. INTRODUCTION 
Insulin secretion from pancreatic fl-cells is 
stimulated by glucose [1]. Glucose application 
causes a slow depolarization, due to the closure of 
ATP-regulated K + channels, which then evokes a 
repetitive pattern of electrical activity during which 
Ca 2+ flows in through voltage-dependent Ca 2+ 
channels and triggers insulin release [2-4]. 
Important progress has recently been made in 
the pharmacology of the ATP-regulated K + chan- 
nel. This channel has been shown to be the target 
of antidiabetic sulfonylureas [5-8]. One of them, 
glibencl.amide, appears to be a very potent blocker 
(Kd in the 0.1-1 nM range) of the ATP-regulated 
K + channel (KATP) [6,7]. 
This channel has also been shown to he activated 
by a hyperglycemia-inducing hormone, galanin 
[9]. Somatostatin is an important hormone in the 
control of inhibition of insulin secretion by the 
pancreatic ~-cell [10]. 
We demonstrate in this paper that somatostatin, 
like galanin, activates ulfonylurea-sensitive K +
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channels and that this activation involves a G- 
protein. 
2. MATERIALS 
2.1. Materials 
Glibenclamide was from Hoechst, somatostatin-14 from 
Bachem and pertussis toxin from List Biological Laboratories 
(Campbell, CA). 
2.2. Cell culture 
RINm5F cells, an insulin-producing cell line derived from a 
rat islet cell tumor, were grown as described in [11]. Cells were 
plated at a density of 200000 cells per well (Falcon 24-well tissue 
culture plates). 
2.3. S6Rb + efflux experiments 
Efflux studies were done according to [7,9] in 24-well culture 
plates at 37°C and after overnight equilibration of cells in 
RPMI 1640 medium supplemented with 10% fetal calf serum, 
0.1/~Ci of S6RbC1 per ml (1 Ci = 37 GBq), and 0.2/~Ci of L- 
[3H]leucine per ml (internal marker of cell recovery). After 
removing the medium, ceils were preincubated, for various 
times as indicated, in a medium of 120 mM NaCI, 1.8 mM 
CaCI2, 0.8 mM MgC12, 10raM KCI containing 20mM 
Hepes/NaOH buffer, pH 7.5, supplemented by 0.1/zCi of 
S6RbC1 per ml without (5 mM glucose added) or with 0.24/zg of 
oligomycin per ml, 1 mM 2-deoxy-D-giucose, and ligands as in- 
dicated in the figures. S6Rb+ efflux studies were initiated by 
removing the preincubation medium and incubating the cells 
with 200/A per cell of the same medium without S6Rb+, and 
without or with oligomycin, and 2-deoxy-D-giucose. Efflux was 
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stopped by removing the latter medium and washing the cells 
three times with 1 ml of 0.1 M MgCl2 at 37°C. Cells were ex- 
tracted with two 1-ml portions of 0.1 M NaOH, and radioac- 
tivity was counted. 
2.4. Pertussis toxin treatment 
RINm5F cells were incubated for 15 h in complete culture 
medium with 100 ng of pertussis toxin per ml at 37°C before 
a6Rb+ efflux experiments. 
3. RESULTS AND DISCUSSION 
This laboratory has previously shown that the 
86Rb+ efflux technique can be very useful to study 
the activity of ATP-regulated K + channels in in- 
sulinoma RINm5F cells [7,9]. Lowering of in- 
tracellular ATP by oligomycin and 2-deoxy-D- 
glucose treatment reveals an important component 
of the 86Rb+ efflux as can be seen again in fig. 1A. 
This component of the 86Rb+ efflux is completely 
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Fig.1. Kinetics of S6Rb+ efflux from RINm5F cells: effect of 
ATP depletion and somatostatin. (A) Kinetics of 86Rb+ efflux 
without depletion of [ATP]in (e) or after depletion of [ATP]in 
for 15 min in the absence (A) or presence (n) of 100 nM 
glibenclamide. (B) Kinetics of activation of 86Rb+ efftux 
without depletion of [ATP]in by 100 nM somatostatin i  the 
absence (•) or presence (z~) of 100 nM glibenclamide. (Control) 
Kinetics of 86Rb+ efflux without depletion of [ATP]in (0). 
eliminated / by the potent sulfonylurea 
glibenclamid~e [7]. 
Interestingly somatostatin also stimulates an in- 
crease of 86Rb+ efflux but then it is not necessary 
to decrease the intracellular ATP concentration to
observe the hormonal activation of ATP-regulated 
K + channels. The activation presented in fig.lB 
was observed with an intracellular ATP concentra- 
tion of 4.0 + 0.5 mM. 
Somatostatin activation of 86Rb+ efflux was 
eliminated by the blocker of ATP-regulated K ÷ 
channels, glibenclamide. 
The concentration dependence of the 
somatostatin effect on the activity of the 
glibenclamide-sensitive K+ channel is presented in 
fig.2. Half-maximal activation by the hormone 
was observed at Ko.5 = 0.7 _ 0.2 nM which is 
similar to the value (K0.5 = 1.6 nM) for half- 
maximal activation of KATe channels by galanin 
[9]. 
A very interesting aspect of the effect of 
somatostatin on glibenclamide- (and ATP-)sen- 
sitive K ÷ channels is that the hormonal effect is 
abolished by pretreatment with pertussis toxin 
(fig.3). This observation clearly indicates that the 
somatostatin control of ATP-regulated K + chan- 
nels in insulinoma cells involves a G-protein. It re- 
mains to be seen whether the pertussis 
toxin-sensitive G-protein is involved in a direct 
coupling between the somatostatin receptor and 
the ATP-regulated K ÷ channel or whether the key 
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Fig.2. Dose-response curve for the activation of the 
glibenclamide-sensitive 86Rb* efflux by somatostatin without 
[ATP]in depletion, a6Rb+ efflux was measured at 1 min. 
Somatostatin was pre-incubated for 3 min before the start of 
the flux experiments. Bars indicate means +_ SE (n = 5 
experiments in duplicate). 
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Fig.3. Kinetics of activation of S6Rb+ efflux without depletion 
of [ATP]i, by 10 nM of somatostatin in the absence (n)  or after 
treatment (o) with 100 ng/ml of pertussis toxin. 
G-protein is associated with the regulation of levels 
of an intracellular messenger which, in turn, can 
regulate the activity of the channel. Involvement of 
a G-protein in the galanin activation of ATP- 
regulated K + channel [9] has also been 
demonstrated independently (Petersen, O.H., per- 
sonal communication). 
Somatostatin after galanin [9] is the second hor- 
mone described which decreases insulin release and 
which apparently does it, at least partly, by ac- 
tivating a KATP channel. This observation definite- 
ly shows that the KATe channel plays a key role in 
insulin secretion. It is activated by hyperglycemia- 
inducing hormones and inhibited by sulfonylureas 
[5-8] that are so largely utilized in the treatment of 
type II diabetes. 
It has been shown previously that somatostatin 
induces hyperpolarization in a corticotropin- 
secreting cell line and that this event is correlated 
with an activation of an inward rectifying K + con- 
ductance [12-15]. It will be important to see 
whether this K + channel is also ATP-regulated and 
sensitive to sulfonylureas. 
The other information of importance in this 
paper is that there are clearly two different ways to 
activate the sulfonylurea-sensitive K + channel. The 
first one is the now classical regulation associated 
to a decrease of ATP concentration. The second 
one occurs at high intracellular ATP concentration 
and is associated to an activation of the channel 
with hormones. Therefore the physiological 
trol of the activity of this channel is probably not 
limited to a control via variations of intracellular 
ATP concentrations (which probably relates in- 
sulin secretion to glucose perfusion). Opening of 
the sulfonylurea-sensitive channel under the in- 
fluence of peptide hormones without changing in- 
tracellular ATP might be the really important 
physiological event. It would be interesting to 
analyze the properties of somatostatin activation 
of the sulfonylurea-sensitive K ÷ channel in E-cells 
from diabetic pancreas. 
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